- Dupilumab reduced severe exacerbations in adults with uncontrolled, moderate-to-severe asthma with onset >40 years old.
Why this matters
- Previous results established dupilumab efficacy for uncontrolled, moderate-to-severe asthma but did not report data for late-onset asthma with fixed airway obstruction.
- Post hoc analysis of randomized controlled trial with patients with uncontrolled, moderate-to-severe, late-onset (age >40 years) asthma with baseline post-bronchodilator FEV1
- FEV1 ≥0.7: 200 mg q2w dupilumab (n=74) or placebo (n=38) and 300 mg q2w dupilumab (n=72) or placebo (n=41).
- Dupilumab significantly reduced annualized rate of severe exacerbations:
- FEV1 ≥0.7: −55.1% (200 mg) and −50.7% (300 mg) (P<.05 class="">
- Patients with FEV1
- Pre-bronchodilator FEV1 from baseline to week 12 (200 mg, P=.01; 300 mg, P=.003) and week 52 (200 mg, P=.004).
- Post-bronchodilator FEV1 to week 12 (300 mg, P=.003) and week 52 (200 mg, P=.01).